Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. - Wikidata - awgldk - TriplyDB

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

http://www.wikidata.org/entity/Q39279366

about

Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal Notch signaling in prostate cancer: refining a therapeutic opportunity Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer The Role of Hedgehog Signaling in Tumor Induced Bone Disease Insights into Chemoresistance of Prostate Cancer Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications Hedgehog Signaling in the Maintenance of Cancer Stem Cells Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations MicroRNAs targeting prostate cancer stem cells Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells Using circulating tumor cells to inform on prostate cancer biology and clinical utility The role of GLI1 for 5-Fu resistance in colorectal cancer Current status and perspectives of patient-derived xenograft models in cancer research.GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer Prostate cancer and bone: the elective affinities.Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.The role of GATA2 in lethal prostate cancer aggressiveness.Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer Notch inhibitors for cancer treatment.Molecular pathways and targets in prostate cancer Berberis libanotica Ehrenb extract shows anti-neoplastic effects on prostate cancer stem/progenitor cells.Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer Notch signaling in serous ovarian cancer.The role of epithelial plasticity in prostate cancer dissemination and treatment resistance Dissociated primary human prostate cancer cells coinjected with the immortalized Hs5 bone marrow stromal cells generate undifferentiated tumors in NOD/SCID-γ mice.Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer The biology of castration-resistant prostate cancer Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression.Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression.Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.SOX18 Is a Novel Target Gene of Hedgehog Signaling in Cervical Carcinoma Cell Lines.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.The Hedgehog pathway: role in cell differentiation, polarity and proliferation Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis.

P2860

Q26744536-DB835680-BBF3-45B0-9FB7-C3A16C182872 Q26777624-CBCDAFCE-10F3-4835-B8BC-5797A8F081FB Q26783028-2B793422-51F7-4D67-836C-8EBB064916AF Q26783615-34E42A23-E56B-4BE4-98A1-F8B69DD86C94 Q26795589-05615AAC-DFCD-44D1-A29E-470C82853F47 Q26797063-EB8A4556-969E-4C87-B12C-269FF444B2C4 Q26798191-C8FDEB5A-29A2-4574-A8C7-A641EA439DFB Q26865136-5EA1993D-0693-4DC6-8503-389FED06324F Q27341759-39BF9445-59FC-4377-A683-7FCFCAF902F8 Q27853127-17849ABB-AB7C-4074-8C71-2BCF0BB6F2F2 Q28080701-D7CB32ED-937B-41F1-BB2E-89E231F1D27B Q28081039-1C8FE775-57FB-46C7-9D02-63285659FDBC Q28081405-2F624DB2-5C80-4F35-B4D9-BAE40506692A Q28083261-7503655A-EDD4-4217-BAAF-665A8CD4C31A Q33560768-77F84899-9B80-4C48-9289-49286148DC8D Q33667686-F5DAA9F3-3549-459F-A5FC-DEB4724215ED Q33689071-DC39CE5C-FAF5-4A90-B4DB-E83977AAA845 Q33757791-22D69393-3FC4-470D-B9AD-04F642243CC8 Q33798364-AAD8311E-FCB4-4122-879E-C06A775C60F0 Q33848134-6E5E525E-CCCA-4327-BCA3-AE895A9CBDC2 Q34265065-89F94FEF-FE18-4767-A622-26A3428E28A3 Q34330869-9D51A563-30BD-4A42-A5D5-8CD3D2599C5A Q34365632-F9C61487-DFF8-4B77-9FE5-6D5C81F8F988 Q34473310-3E092C97-20A1-44E2-B9EF-C6E4AF2CC4EB Q34477201-5C333870-DE25-469C-BCAC-EA83446887F1 Q34491211-142CFA51-91EE-4FB3-AA15-EAC27BB562E3 Q34505037-207A74E0-2BBF-46CF-9EF7-ECB6DC0E32E0 Q34602712-03C1A365-6B73-462B-AA72-FEC024B6B153 Q34608976-B218851F-B935-43AE-AEFC-1EA5F4831BC9 Q35039889-51F5A6AD-41F1-4F6A-9A40-90C6F7CA0D98 Q35551899-8C5B708B-23C5-4C2F-8D1B-DED9921BBACD Q35562215-140B3338-7C99-4B5C-BB0B-15A6A9EA1E15 Q35672901-2D12AF79-93E9-4D96-9D2B-E05002C10105 Q35806000-D3B14BCD-8612-4BF5-8C4B-F1898B2A9EAE Q35847295-FBCB1C91-5E82-4D9F-A851-89487838B63E Q35904534-A2961AAA-84F8-4842-84E0-210C13B3E734 Q36070523-60C6B344-09F2-4FDB-B7C0-2B80A9A5B9DA Q36240079-4D6DAFBD-8691-4D96-94A8-D8704E9F9F24 Q36278738-AD0A41F8-101D-4F45-A14B-A6F085F8E9A9 Q36352164-6E5631F3-1667-4716-BA1E-C1DA98C89383

P2860

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

http://www.wikidata.org/entity/Q39279366

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Suppression of acquired doceta ...... endent tumor-initiating cells.

@en

Suppression of acquired doceta ...... endent tumor-initiating cells.

@nl

type

label

Suppression of acquired doceta ...... endent tumor-initiating cells.

@en

Suppression of acquired doceta ...... endent tumor-initiating cells.

@nl

prefLabel

Suppression of acquired doceta ...... endent tumor-initiating cells.

@en

Suppression of acquired doceta ...... endent tumor-initiating cells.

@nl

P1433

Q39279366-9E2A9A7A-FDBB-408B-815D-69BE314C4A15

P1476

Q39279366-C57C4743-BB13-4007-AF6A-9DE2EE5EFAE2

P2093

Q39279366-00CFB7E0-6193-4A06-BB8C-8F2EBB7ADF3C

Q39279366-1B73A6EE-751F-4B8B-A471-91D9A3F0C199

Q39279366-64CA0A84-DC69-45B6-ABBD-6B2D186B2B33

Q39279366-6B814AB5-E1F5-4A64-8D0F-35DDF74F52DB

Q39279366-6E2F1DCC-51BC-4FE2-944A-7A2308B2544F

Q39279366-75B68D39-247A-44AC-8E71-E8A3944AABF7

Q39279366-7F02BB68-50AF-43A1-B745-E4A1393816E6

Q39279366-8CE642A2-47D1-4A67-8E8A-13168503EE09

Q39279366-B17D8A52-143D-408F-9F28-F29D2143EAC1

Q39279366-F0C5B60D-62FC-43BF-A80D-53A73EC5F49E

P2860

Q39279366-07A6C668-2B92-4A17-8A32-3E6A6438B0E1

Q39279366-12139910-9D28-4056-87A9-0F251B757A25

Q39279366-131B2F47-0993-491B-9B50-4FA7CCFC7E75

Q39279366-1C83FCE9-7B7F-4AAA-8C8D-25E9F6245DB1

Q39279366-225C0A58-CE76-4885-A0DB-24B26F000F47

Q39279366-2528EEB1-F009-4982-A0CE-A3B3F484F4CB

Q39279366-2794EC90-1BB4-4316-8EFB-E8916F9A6CBA

Q39279366-27A14AA1-F1A7-4CCB-92BF-A28BB101A9D7

Q39279366-27F0B63B-0873-444B-9FB4-58BCDDE2712F

Q39279366-2BF17CE0-06E6-4E5E-8340-F1BC5561CCD9

P304

Q39279366-ACC11055-36F6-46CD-AC5E-62BCD251A5A3

P31

Q39279366-622F902F-12F4-4E1C-BEEF-747D7B4547C6

P356

Q39279366-2904B8DF-C46A-4DF7-8A57-B52DD6472959

P433

Q39279366-57ADE9C2-EE51-4975-8197-95F4A4445FEE

P478

Q39279366-2F35BEA1-EBAA-451B-BD21-B33E629FEBD0

P50

Q39279366-0298634B-0B8C-4D8A-95B1-923350AE5CF2

Q39279366-5795FDBF-84C4-43A2-B42F-D6CC995BF555

Q39279366-BBEFB147-AE3A-4ABF-B576-FC3A45143021

P577

Q39279366-C5D94DD7-3C97-4B09-8DCB-3912FB292CF8

P5875

Q39279366-384387A3-F7EA-413D-83E2-E14A1AAEBB18

P698

Q39279366-7E313188-4ACC-4C44-BE40-FB9D64486CA7

P932

Q39279366-824F7706-4D86-418E-9C43-AC6C3E8546A4

P356

J.CCR.2012.07.016

P1433

P1476

Suppression of acquired doceta ...... pendent tumor-initiating cells

@en

P2093

Carlos Cordon-Cardo

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

Dennis M Bonal

http://www.w3.org/2001/XMLSchema#string

Elizabeth Charytonowicz

http://www.w3.org/2001/XMLSchema#string

Janis de la Iglesia-Vicente

http://www.w3.org/2001/XMLSchema#string

Jose M Silva

http://www.w3.org/2001/XMLSchema#string

Josep Domingo-Domenech

http://www.w3.org/2001/XMLSchema#string

Mireia Castillo-Martin

http://www.w3.org/2001/XMLSchema#string

Mitchell C Benson

http://www.w3.org/2001/XMLSchema#string

Nataliya Gladoun

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened

Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine

Multidrug resistance in cancer: role of ATP-dependent transporters

let-7 regulates self renewal and tumorigenicity of breast cancer cells

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

P304

373-388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2012.07.016

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Ruth Rodriguez-Barrueco

V Rodriguez-Bravo

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230848788

http://www.w3.org/2001/XMLSchema#string

P698

22975379

http://www.w3.org/2001/XMLSchema#string

P932

5989708

http://www.w3.org/2001/XMLSchema#string